RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00147420|
Recruitment Status : Completed
First Posted : September 7, 2005
Last Update Posted : December 17, 2013
|Condition or disease||Intervention/treatment|
|Hemorrhage||Drug: Zhi Byed 11|
Post-partum hemorrhage (PPH) is one of the main direct causes of maternal mortality, particularly in rural areas with low access to skilled providers, blood banks, and surgical facilities. In addition to the mortality, PPH also accounts for a great number of morbidities, including anemia, renal and pulmonary problems, fatigue, and decreased resistance to infection, all major health problems affecting women in the TAR. Clinical research is rare in the Tibetan Autonomous Region (TAR) of the People's Republic of China. This trial will estimate the effect of prophylactic oral ZB 11 administered at the beginning of the second stage of labor versus prophylactic oral misoprostol, administered in the third stage of labor, in reducing the incidence of postpartum hemorrhage (defined as a measured blood loss of > 500 cc).
An observational postpartum blood measurement study was conducted. This included data collection on deliveries in three TAR hospital in Lhasa, piloting of consent forms and data collection instruments, and training in the use of a plastic drape for the measurement of postpartum blood loss.
This randomized, double masked trial will test the hypothesis that misoprostol is more effective than ZB11 in reducing the frequency of postpartum hemorrhage (defined as either a measured blood loss of > 500cc or administration of open label uterotonics within the one hour observation period after delivery).
An original sample of 848 women was increased and 967 consenting women were randomized (1:1) to a ZB11 or misoprostol arm. Since ZB 11 and misoprostol must be administered at different times, participants will receive either active ZB 11 or corresponding placebo at full dilation and active misoprostol or corresponding placebo immediately following the birth of the baby. The effectiveness of the study drug will be estimated by the postpartum blood loss that will be measured on all enrolled women with a blood collection drape.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||848 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet|
|Study Start Date :||September 2005|
|Study Completion Date :||March 2007|
- Postpartum hemorrhage
- Maternal death
- Estimated average blood loss of women during birth
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00147420
|Lhasa Maternal-Child Health (MCH) Hospital|
|Lhasa Municipal Hospital|
|The Mentzikhang Traditional Tibetan Medicine and Astrology Hospital|
|Principal Investigator:||Michael Varner, MD||University of Utah|